Novato, CA, United States
Novato, CA, United States

Time filter

Source Type

Patent
Raptor Pharmaceuticals | Date: 2016-08-01

The present disclosure relates, in general, to compounds useful as inhibitors of fucosidase enzymes, and to methods and compositions for the treatment of tumors or cancers, such as liver disorders and liver tumors (e.g., hepatocellular carcinoma), with a compound as disclosed herein.


Patent
Raptor Pharmaceuticals | Date: 2015-10-30

Provided herein are 4-methylpyrazole (4-MP) formulations, stable under storage conditions of up to about 55 C.


Patent
Raptor Pharmaceuticals | Date: 2016-04-18

The present invention relates to the field of antimicrobial agents. In particular, the present invention relates to the use of aerosolized fluoroquinolones formulated with divalent or trivalent cations and having improved pulmonary availability for the treatment and management of bacterial infections of the lung and upper respiratory tract.


Patent
Raptor Pharmaceuticals | Date: 2016-07-05

The present disclosure is directed to methods for treating diseases for which cysteamine is indicated and compounds useful in such methods.


An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.


Patent
Raptor Pharmaceuticals | Date: 2016-09-20

Provided herein are methods of administering 4-methylpyrazole (4-MP), or physiologically acceptable salts thereof, to subjects of genetic subpopulations expressing specific polymorphisms of the alcohol dehydrogenase and aldehyde dehydro genase genes. Also provided herein are methods to prevent or ameliorate ethanol intolerance, reduce or ameliorate symptoms associated with acetaldehyde accumulation accompanying ethanol consumption, or reduce the risk of diseases or disorders caused by consumption of ethanol, comprising administering 4-MP, or physiologically acceptable salts thereof, to subjects of these subpopulations.


Patent
Raptor Pharmaceuticals | Date: 2016-08-05

Methods of analyzing purity of compositions comprising cysteamine and detecting impurities in cysteamine compositions are described.


Patent
Raptor Pharmaceuticals | Date: 2016-06-03

Disclosed herein are formulations of fluoroquinolones suitable for aerosolization and use of such formulations for aerosol administration of fluoroquinolone antimicrobials for the treatment of pulmonary bacterial infections. In particular, inhaled levofloxacin specifically formulated and delivered for bacterial infections of the lungs is described. Methods include inhalation protocols and manufacturing procedures for production and use of the compositions described.


An enteric-coated bead dosage form of cysteamine, and related methods of manufacture and use, are disclosed.


Patent
Raptor Pharmaceuticals | Date: 2016-05-02

Provided herein are methods, compositions and formulations to prevent or ameliorate ethanol intolerance, reduce or ameliorate symptoms associated with acetaldehyde accumulation accompanying ethanol consumption, or reduce the risk of diseases or disorders caused by acetaldehyde accumulation, comprising administering 4-MP, or physiologically acceptable salts thereof, to subjects with reduced or absent aldehyde dehydrogenase subtype 2 (ALDH2) activity.

Loading Raptor Pharmaceuticals collaborators
Loading Raptor Pharmaceuticals collaborators